Sanara MedTech Q1 EPS $(0.21) Misses $(0.07) Estimate, Sales $18.54M Beat $18.50M Estimate
Portfolio Pulse from Benzinga Newsdesk
Sanara MedTech reported Q1 EPS of $(0.21), missing estimates by 200% and marking a 50% increase in losses from the previous year. However, their sales of $18.54M exceeded estimates slightly by 0.20% and showed a 19.42% increase from the previous year.
May 13, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Sanara MedTech's Q1 earnings missed estimates significantly, with a 200% miss on EPS but reported a slight beat on sales estimates with a 19.42% YOY increase.
The significant miss on EPS could negatively impact investor sentiment, but the slight beat on sales and the year-over-year growth might offset some of the negative impact. The mixed results present a neutral short-term outlook as investors weigh the underperformance in earnings against the sales growth.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100